

1/21


FIGURES


FIG. 1







HC102






HC103





rAd HC102

FIG. 5



COS-7





FIG. 7


COS-7



10/528644 PCT/KR03/01951 RO/KR 19. 11. 2003

6/21 FIG. 8

<u>293A</u>



7/21

FIG. 9

Optimization of insert size

(5 weeks after immunization)

E2 specific IFN-r ELISPOT & CTL response target cell: 2x104 CT26-hghE2t/well






FIG. 10

Optimization of insert size


(3, 4 weeks after boosting)





E2 specific IFN-r ELISPOT & CTL response target cell: 2x10⁴ CT26-hghE2t/well



8/21 FIG. 11









Truncation of E2 TM domain


5 weeks after immunization

3.4 weeks after boosting








a. E2 specific IFN-γ ELISPOT




core specific IFN-γELISPOT








core specific IL-4 ELISPOT d.



naive :saline injected control

- G 1: pGX10 gDsAST + pGX10 mIL-12mutant injection -> pGX10 gDsΔST + pGX10
- mIL-12mutant injection
 G 2: pGX10 gDsAST + pGX10 G 2: pGX10 gDsA51 + pGX10
 mlL-12mutant injection ->
 rAd gDsA5T injection
 G 3: rAd gDsA5T injection
 G 4: rAd gDsA5T injection
 G 4: rAd gDsA5T injection ->
 pGX10 gDsA5T epGX10
- mIL-12mutant injection

11/21 FIG. 14




12/21


FIG. 15

(schedule)


DNA prime/ rAd boost




13/21 FIG. 16




14/21 FIG. 17



15/21 FIG. 18



16/21 FIG. 19




* mean amount of HCV RNA with triplicate measurement, one of which was below the detection limit.

17/21 FIG. 20a

Amino acid sequence of core peptide pool

	ΔCore	· (43-191)
No	Name	Sequence
#1	HCV43-62	RLGURATRKT SERSOPRGRR
#2	HCV53-72	SERSOPRGRR OPIPKAROPE
#3	HCV63-82	QPIPKARQPE GRTWAQPGYP
#4	HCV73-92	GRTWAQPGYP WPLYGMEGLG
#5	HCV83-102	WPLYGNEGLG WAGWLL3PRG
#6	HCV93-112	WAGWLLSPRG SRPSWGPTDP
#7	HCV103-122	SRPSWGPTDP RRRSRMLGKV
#8	HCV113-132	RRRSRWLGKU IDTLTCGFAD
#9	HCV123-142	IDTLTCGFAD LMGYIPLVGA
#10	HCV133-152	LMGYIPLUGA PLGGUARALA
#11	HCV143-152	PLGGVARALA HGVRLLEDGV
#12	HCV153-172	HGURLLEDGU MYATGMLPGC



18/21 FIG. 20b

Amino acid sequence of E2t peptide pool

		E2t (3	84-71	3)	
No	Mame	Sequence	Мo	Mame	Sequence
#13	HCV384-403	STRUTGGTEG RTTMRFUSIF	#29	HCV554-573	MMMSTGITKT CGGPPCDIGG
#14	HCV404-423	ASGPSQKIQL UMMMGSWHIM	\$ 30	HCV564-583	CGGPPCDIGG VGNMTLTCPT
#15	HCV414-433	UMMEGSWHIM RTALECHDSL	#31	HCV574-593	VGMMTLTCPT DCFRKHPEAT
#15	HCU424-443	RTALNONDSL SSGFIAALFY	#32	HCV584-603	DCFRKHPEAT YTKCGSGPWL
#17	HCU434-453	SSGFIAALFY THEFDSSGCP	#33	HCV594-613	YTKCGSGPWL TPRCMVDYPY
#18	HCV444-463	THE	#34	HCV504-523	TPRCMVDYPY RLWHYPCT IN
#19	HCU454-473	ERMASCRPID KFAQGWGSIT	#35	HCV614-633	RLUHYPCTIN FTIFKURMYU
#20	HCU464-483	KFAQGWGSIT YAESGGSDQR	#35	HCU524-543	FT IFKVRMYV GGVEHRLDAA
#21	HCV474-493	YAESGGSDQR PYCWHYAPRQ	#37	HCV634-653	GGVEHRLDAA CMWTRGERCD
#22	HCU484-503	PYCUMYAPRO CGIVPASOUC	#38	HCV544-553	CMWTRGERCD LEDRDRSELS
#23	HCV494-513	CGIVPASQUE GPVYCTTPSP	#35	HCV554-673	LEDRORSELS PLLLSTTEWQ
#24	HCU504-523	GPVYCFTPSP VVVGTTDRSG	#40	HCV564-583	PLLLSTTEWQ VLPCSITTLP
# 25	HCV514-533	UNVGTTDRSG APTYTWGENE	#41	HCV674-593	VLPCSITTLP ALSTGLIHLH
#26	HCU524-543	APTYTUGENE TOULLINNTR	#42	HCV584-703	ALSTGLIHLH QNIVHAQHLH
#27	HCV534-553	TDVLLLMMTR PPQAMWFGCT	#43	HCV694-713	ONICHACHLH GUGSAVUSIV
# 28	HCV544-563	PPQAMWFGCT WMMSTGFTKT			

19/21 FIG. 20c

Amino acid sequence of NS3 protease peptide pool


	NS3 prote	ase (1029-1217)
#44	gHCV-1029	IT AYSQQTRGLLGC I ITSLT
#45	gHCV-1039	LLGCIITSLTGRDKNQVEGE
#46	gHCV-1069	fl at cung awtu fhg ag sk
#47	gHCV-1078	wtvfhgag3ktlagpkgp it
#48	gHCV-1088	TLAGPKGP IT OMYTWODLDL
#49	gHCV-1098	QMYTNUDLDLUGWQAPPG3R
#50	gHCV-1108	VGWQAPPGSRPLTPCTCGSS
#51	gHCV-1118	PLTPCTCGSSDLYLVTRHAD
#52	gHCV-1128	DLYLVTRHADV IPVRRRGDS
#53	gHCV-1138	V IPVRRRGDSRGSLPCPRPV
#54	gHCV-1148	RGSLPCPRPUSYLKGSSGGP
#55	gHCV-1158	SYLKGSSGGPLLCPSGHAUG
#55	gHCV-1158	LLCPSGHAUGIFRAAUCTRG
#57	gHCV-1178	IFRAAUCTRGUAKAUDFIPU
# 58	gHCV-1188	VAKAVDFIPVESMETTMRSP
#59	gHCV-1198	ESMETTMRSPUFTDNSTPPA

10/528644 PCT/KR03/01951 RO/KR 19. 11. 2003

20/21 FIG. 20d

Amino acid sequence of Helicase peptide pool

NS3 helicase (1208-1656)					
Иo	Name	Sequence	Ио	Name	Sequence
# 60	HCV1208-1227	VITONSTPPA VPQTFQVAHL	#77	HCV1458-1477	TOTUDESLOP TET IDTTTUP
# 51	HCV1218-1237	UPQTFQUAHL HAPTGSGKST	#78	HCV1468-1487	TITIDTTTVP QDAVSRSQRR
# 52	HCV1228-1247	HAPTG3GK3T KUPAAYAAQG	#79	HCV1478-1497	QDAUSRSQRR GRTGRGRRGI
# 53	HCV1238-1257	KUPAAYAAQG YKULULMPSU	#80	HCV1488-1507	GRIGRGRRGI YRIVIPGERP
#64	HCV1248-1257	YKULULMPSU AATLGFGUYM	#81	HCV1498-1517	YRIVIPGERP SGMIDSSVLC
#65	HCV1258-1277	AATLGFGVYM. SKAHGIDPNI	#82	HCV1518-1537	ECYDAGCAWY ELTPAETSUR
#66	HCV1258-1287	SKANGIDPNI RTGURAITTG	# 83	HCV1528-1547	ELTPAETSUR LRAYLETPGL
#67	HCV1278-1297	RIGURAITIG APITYSTYGK	#84	HCV1538-1557	LRAYLMTPGL PUCQDHLEFW
# 58	HCV1318-1337	HSTDSTSILG IGTVLDQAET	#35	HCV1548-1567	PUCQDHLEFW ESUFFGLTHI
#69	HCV1328-1347	IGTULDQAET AGARLUULAT	#85	HCV1558-1577	ESVITGLTHI DANFLEQTKQ
#70	HCV1348-1357	ATPPGSUTUP HPWIEEUALS	#87	HCV1568-1587	DAHFLSQTKQ AGDNFPYLVA
#71	HCV1358-1377	HPN IEEUALS NTGE IP FYGK	#88	HCU1578-1597	AGDNIPYLUA YQATUCARAQ
#72	HCV1358-1387	MI GE IP FYGK AIP IEU IKGG	#89	HCV1588-1507	YQATUCARAQ APPPSWDQMW
# 73	HCV1388-1407	RHLIFCHSKK KSDELAAKLS	#90	HCV1598-1517	APPPSWDQMW KCLTRLKPTL
#74	HCV1398-1417	KEDELAAKIE ALGIMAVAYY	#91	HCV1508-1527	KCLTRLKPTL HGPTPLLYRL
#75	HCV1408-1427	ALGLWAVAYY RGLDUSVIPT	#92	HCV1518-1537	HGPTPLLYRL GAUQMEUTLT
# 75	HCV1418-1437	RGLDUSUIPT SGDUUVVATD	#93	HCV1528-1547	GAUQUEUTLT HPUTKFIMAC



21/21 FIG. 20e

Amino acid sequence of NS5A peptide pool

Name ICV-1972 ICV-1982 ICV-2002 ICV-2012 ICV-2012 ICV-2022 ICV-2042 ICV-2052 ICV-2052	Sequence SGSWLRDVWDWICTVLTDFK WICTVLTDFKTWLQSKLLPR TWLQSKLLPRLPGVPFF3CQ LPGVPFF3CQRGYKGVWRGE RGYKGVWRGEGIMQTTCPCG GIMQTTCPCGAQIAGHVKNG SMRIVGPRTCSMTWHGTFPI SMTWHGTFPIMAYTTGPCSP MAYTTGPCSPSPAPMYSRAL	#113 #114 #115 #116 #117 #118 #119 #120	#ame gHCV-2192 gHCV-2202 gHCV-2212 gHCV-2222 gHCV-2232 gHCV-2242 gHCV-2252	Sequence GSPPSLASSSASQLSAPSLK ASQLSAPSLKATCT INHDSP ATCT INHDSPDADL IE ANLL DADL IE ANLLWRQEMGGN IT WRQEMGGN ITRUESEMKUU I RUESEMKUU ILDSTEP IRAE LDSTEP IRAEEDEREUSUPA EDEREUSUPAE ILRRSRKIP
ICV-1982 ICV-1992 ICV-2002 ICV-2012 ICV-2022 ICV-2042 ICV-2042	WICTULTD FKT WLQSKLLPR TWLQSKLLPRLPGUP FF3CQ LPGUP FF3CQRGYKGUWRGE RGYKGUWRGEG IMQTT CPCG GIMQTT CPCGAQ I AGHUKNG SMR IUGPRT CSMT WHGT FP I SMTWHGT FP I MAYTT GPCSP	#114 #115 #116 #117 #118 #119 #120	gHCV-2202 gHCV-2212 gHCV-2222 gHCV-2232 gHCV-2242 gHCV-2252 gHCV-2252	ASQLSAPSLKATCT INHOSP ATCT INHOSPD ADL IE AMLL DADL IE AMLLWRQEMGGN IT WRQEMGGN ITRVESEMKVV I RVESEMKVV ILDSFEP IRAE LDSFEP IRAEEDEREVSVP A
ICV-1992 ICV-2002 ICV-2012 ICV-2022 ICV-2042	TWLQSKLLPRLPGVPFF3CQ LPGVPFF3CQRGYKGVWRGE RGYKGVWRGEGIMQTTCPCG GIMQTTCPCGAQIAGHVKNG SMRIVGPRTCSMTWHGTFPI SMTWHGTFPIMAYTTGPCSP	#115 #116 #117 #118 #119 #120	gHCV-2212 gHCV-2222 gHCV-2232 gHCV-2242 gHCV-2252 gHCV-2252	ATCT INHOSPDADL IE ANLL DADL IE ANLLWRQEMGGN IT WRQEMGGN ITRVESENKOV I RVESENKOV ILDS FEP IRAE LDS FEP IRAEEDEREUSUPA
ICV-2002 ICV-2012 ICV-2022 ICV-2042	LPGUP FF3CQRGYKGUURGE RGYKGUURGEG IMQTTCPCG GIMQTTCPCGAQ I AGHUKNG SMR IUGPRTCSNTWHGI FP I SNTWHGT FP INAYTTGPCSP	#115 #117 #118 #119 #120	gHCV-2222 gHCV-2232 gHCV-2242 gHCV-2252 gHCV-2252	DADL IE ANLLWRQEMGGN IT WRQEMGGN IT RVE SENKVV I RVE SENKVV ILDS FEP IRAE LDS FEP IRAEEDEREVSVPA
ICV-2012 ICV-2022 ICV-2042	RGYKGUWRGEG IMQTTCPCG GIMQTTCPCGAQ IAGHUKNG SMRIUGPRTCSMTWHGTFP I SMTWHGTFP IMAYTTGPCSP	#117 #118 #119 #120	gHCV-2232 gHCV-2242 gHCV-2252 gHCV-2262	WRQEMGGN ITRVESENKOV I RVESENKOV ILDS FEP IRAE LDS FEP IRAEEDEREUSUPA
ICV-2022 ICV-2042 ICV-2052	GIMQTTCPCGAQIAGHUKNG SMRIVGPRTCSNTWHGTFPI SNTWHGTFPINAYTTGPCSP	#118 #119 #120	gHCU-2242 gHCU-2252 gHCU-2252	RVE SENKUV ILDSTEP IRAE LDSTEP IRAEEDEREUSVP A
1CV-2042	SMR IVGPRICSMIWHGIFP I	#119 #120	gHCV-2252 gHCV-2252	LDS FEP IRAEEDEREUSVPA
TCV-2052	SMTWHGT FP INAYTTGPCSP	#120	gHCV-2252	<u> </u>
		 		ederevsvp ae ilrrsrkfp
TCV-2062	naytt gpcspspapnysral	#121		
		1 ~	gHCV-2272	e ilrrərkip amp iwarpd
1CV-2072	SP APWYSR AL WRVA AEEYVE	#122	gHCV-2292	AMBELLERMEDEDAMBEACH
ICV-2082	WRUAAEEYVEVTRUGD FHYV	#123	gHCV-2302	DPDYVPPVVHGCPLPPTKAA
1CV-2092	VTRUGDFHYVTGVTTDMVKC	#124	gHCV-2322	P IPPPRRKRT IVLTESTUSS
1CV-2102	TGVTTDMVKCPCQVPAPEFF	#125	gHCV-2332	IULTESTUSSAL AEL ATKT I
1CV-2122	TELDGURLHRYAPACKPLLR	#125	gHCV-2342	al ael atkt fggsgswaads
ACV-2132	YAP ACKPLLRDEUS FQUGLM	#127	gHCV-2352	GGSGSWAADSGT AT APPDQT
HCV-2152	QYLVG3QLPCEPEPDVAVLT	#128	gHCV-2372	SDD GDKE SDVE SYSSMPPLE
HCV-2152	EPEPDVAVLT SMLTDP SHIT	#129	gHCV-2382	ESYSSMPPLEGEPGDPDLSI
HCV-2172	SMLTDP SH IT AET AKRRL AR	#130	gHCV-2392	GEP GDPDL 3D G 3W 3TV 3EE A
H	CV-2132 CV-2152 CV-2152	CU-2132 YAPACKPLLRDEUSFQUGLW CU-2152 QYLUGSQLPCEPEPDUAULT CU-2162 EPEPDUAULTSMLTDPSHIT	CU-2132 YAPACKPLLRDEUSFQUGLW #127 CU-2152 QYLVGSQLPCEPEPDUAULT #128 CU-2162 EPEPDUAULTSMLTDPSHIT #129	CU-2132 YAPACKPLLRDEUSFQUGLW #127 gHCU-2352 CU-2152 QYLVGSQLPCEPEPDVAVLT #128 gHCU-2372 CU-2162 EPEPDVAVLTSMLTDPSHIT #129 gHCU-2382

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.